Problem-Solving Therapy and Supportive Therapy in Older Adults With Major Depression and Executive Dysfunction
Publication: American Journal of Psychiatry
Abstract
Objective:
The purpose of this study was to determine whether problem-solving therapy is an effective treatment in older patients with depression and executive dysfunction, a population likely to be resistant to antidepressant drugs.
Method:
Participants were adults age 60 and older with major depression and executive dysfunction. Problem-solving therapy was modified to be accessible to this population. Participants were randomly assigned to 12 weekly sessions of problem-solving therapy or supportive therapy and assessed at weeks 3, 6, 9, and 12.
Results:
Of the 653 individuals referred for this study, 221 met selection criteria and were enrolled in the study. Reduction of depressive symptom severity was comparable for the two treatment groups during the first 6 weeks of treatment, but at weeks 9 and 12 the problem-solving therapy group had a greater reduction in symptom severity, a greater response rate, and a greater remission rate than the supportive therapy group (response rates at week 9: 47.1% and 29.3%; at week 12:56.7% and 34.0%; remission rates at week 9: 37.9% and 21.7%; at week 12: 45.6% and 27.8%). Problem-solving therapy yielded one additional response or remission over supportive therapy for every 4.4–5.6 patients by the end of the trial.
Conclusions:
These results suggest that problem-solving therapy is effective in reducing depressive symptoms and leading to treatment response and remission in a considerable number of older patients with major depression and executive dysfunction. The clinical value of this finding is that problem-solving therapy may be a treatment alternative in an older patient population likely to be resistant to pharmacotherapy.
Executive dysfunction is common in late-life depression (1, 2) and predicts slow, poor, and unstable response to antidepressant agents (3–6). This observation initiated research that identified structural (7) and functional (1, 8) brain abnormalities underlying executive dysfunction and interfering with antidepressant response. Pharmacological approaches to depression with executive dysfunction may be guided by emerging knowledge of the biological abnormalities of these patients.
In a parallel effort, we proposed a nonpharmacological intervention (9). We envisioned this intervention as treatment that maximizes patients' skills in addressing problems originating from their depressive symptoms and executive dysfunction and reduces the chronic experience of stress. Depression with executive dysfunction has a rather distinct clinical presentation. Compared to cognitively intact depressed older patients, patients with major depression and executive dysfunction are more likely to have psychomotor retardation, apathy, lack of insight into their illness, and behavioral disability disproportionate to the severity of their depression (2). Their disability is hardly surprising since the behavioral expression of executive dysfunction consists of difficulties in goal-setting, planning, initiating and sequencing behavior, and terminating behavior when goals are accomplished (1). Disability resulting from the behavioral deficits of executive dysfunction exposes depressed older patients to chronic stress that may contribute to their poor outcomes.
Imparting problem-solving skills to depressed older patients with executive dysfunction is a rational treatment approach because it has the potential to mitigate their behavioral disability. Problem-solving therapy, a depression treatment, is based on the premise that helping patients become better managers of their lives reduces stress and thus ameliorates depression (10). Problem-solving therapy trains patients to identify problems central to their well-being and provides a method for selecting and implementing problem-solving plans. It is effective in older adults with depressive syndromes (11), medical problems (12), and disabilities (13) as well as in younger patients with mental disorders accompanied by executive dysfunction (14).
We used problem-solving therapy as our intervention's theoretical basis and modified it to make it usable by depressed older adults with executive dysfunction. We selected the Nezu et al. (15) social problem-solving structure because of its sequenced approach to teaching problem solving and its emphasis on problem orientation, a critical element of problem-solving therapy (16). In our modification, we retained the therapy's original five steps in targeting problems and arriving at and implementing action plans. In the modified version, the therapist is more directive than in the original version, and patients may focus on less complex problems to facilitate learning. Similarly, the modified version provides more structure on selecting triggers for initiating action plans, sequencing actions, and terminating action once desirable goals are accomplished. In this study, we tested the hypothesis that modified problem-solving therapy leads to a greater reduction of depressive symptoms, a greater response rate, and a greater remission rate over a period of 12 weeks than supportive therapy in depressed older adults with executive dysfunction.
Method
This was a two-site randomized controlled trial comparing a modified version of problem-solving therapy to supportive therapy in older patients with major depression and executive dysfunction. The study protocol was approved by the institutional review boards of both sites. Participants provided written informed consent after receiving a complete description of the study.
Systematic Assessment and Selection Criteria
Potential participants age 60 and older were interviewed with the Structured Clinical Interview for DSM-IV (SCID). Baseline interviews were conducted by interviewers credentialed by the Cornell Advanced Center for Services Research. Diagnoses were assigned by investigators after review of the clinical history, the SCID data, and all other available data during research case conferences. Severity of depression was quantified with the 24-item Hamilton Depression Rating Scale (HAM-D) (17). Based on 56 interviews over the course of the study, interrater reliability for the HAM-D was found to be satisfactory, with an intraclass correlation coefficient of 0.80. Overall cognitive impairment was assessed with the Mini-Mental State Examination (MMSE) (18). Executive functioning was assessed with the Wisconsin Card Sorting Test (19), the Trail Making Test, Part B (20), and the Frontal Systems Behavior Scale (21). Measures related to psychopathology included age at onset of first episode of major depression, neuroticism (from the neuroticism subscale of the NEO Personality Inventory [22]), and history of antidepressant use (from the Composite Antidepressant Treatment Intensity Scale modified to include newer antidepressants [23]). Medical burden was assessed with the Charlson comorbidity index (24), and disability with the 14-item World Health Organization Disability Assessment Schedule (25). Baseline variables related to demographic characteristics, cognitive functions, psychopathology, medical burden, and disability were used in analyses of treatment moderators. All measures were selected for their documented validity and reliability in older adults.
To be eligible for the study, individuals had to meet DSM-IV criteria for major depression and have a score >20 on the HAMD, a score >24 on the MMSE, a score <33 on the initiation/perseveration subscale of the Mattis Dementia Rating Scale (26), and a score <25 on the Stroop Color-Word Test (27). These measures of executive function were selected for their utility in detecting executive dysfunction in late-life depression and the association of poor scores on these instruments with poor response to anti-depressant medication (4).
Exclusion criteria included current treatment with psychotherapy or antidepressants; psychotic depression as indicated on the SCID; a high suicide risk (i.e., intent or plan to attempt suicide in the near future); any axis I disorder other than unipolar major depression and generalized anxiety disorder; antisocial personality disorder; a history of head trauma; dementia (an MMSE score <24 or a DSM-IV diagnosis of dementia); acute or severe medical illness (e.g., delirium, metastatic cancer, decompensated cardiac, liver, or kidney failure, major surgery, stroke, or myocardial infarction during the previous 3 months); use of drugs known to cause depression (e.g., reserpine, alpha-methyl-dopa, steroids); and inability to perform one or more activities of daily living even with assistance (e.g., walking with a cane was not an exclusion criterion). Less than 2% were taking benzodiazepines or sleep aids, and none were taking cognitive enhancers.
After baseline assessment, the HAM-D and the World Health Organization Disability Assessment Schedule were administered again at weeks 3, 6, 9, and 12. Transportation to assessment and treatment sessions was provided. Participants were compensated for time spent in assessments, but not treatment sessions.
Randomization
Participants were assigned to problem-solving therapy or supportive therapy within each site using random numbers in blocks of five participants. Raters were unaware of participants' randomization status and the study hypotheses. Therapists were aware of participants' randomization status but not the study hypotheses.
Problem-Solving Therapy
Treatment consists of 12 weekly sessions to teach participants a five-step problem-solving model (P.A. Arean et al, unpublished manuscript, 2003). This model is taught over the first 5 weeks of treatment, and subsequent sessions are dedicated to refining problem-solving skills. Participants set treatment goals; discuss and evaluate different ways to reach goals; create action plans; and evaluate their effectiveness in reaching goals. Participants are expected to implement plans and apply the problem-solving model to additional problems between sessions. In the last two sessions, participants create a relapse prevention plan using the problem-solving therapy model.
Supportive Therapy
Supportive therapy is a manualized therapy (M.S. Sachs, Cornell University, unpublished manuscript, 2000) similar to person-centered psychotherapy and consists of 12 weekly individual sessions. Therapists create a comfortable, nonjudgmental environment by demonstrating genuineness, empathy, and acceptance of patients without imposing any judgments on their decisions. This approach aids patients in addressing problems without direct input from therapists. Participants are encouraged to talk about their depression and any contributing life events. Therapists do not engage in any therapeutic strategy other than active listening and offering support focusing on participants' problems and concerns.
Therapist Intervention Adherence and Quality
Four doctoral-level clinical psychologists and four licensed social workers with at least 5 years of postlicensure experience served as therapists. None had prior experience with problem-solving therapy or supportive therapy, and each therapist was trained in both therapies. To control for potential bias resulting from therapists offering both treatments, all therapists participated in extensive training and were closely monitored to ensure that both treatments were provided with high quality. Training consisted of a 2-day workshop and supervision of six training cases (three per treatment). Fidelity monitoring consisted of review of randomly selected audiotapes (20%), rated by independent experts in both treatments using the Problem-Solving Therapy Adherence Scale (28) for problem-solving therapy and the California Psychotherapy Assessment Scale (29) for supportive therapy. Average therapist ratings for both treatments were excellent and ranged between excellent and exceptional. No differences in quality ratings were observed for any therapist for either treatment.
Data Analysis
Two separate analyses were performed on data from all participants who completed the baseline assessment (the intent-to-treat sample). First, profiles of pretreatment and weekly HAM-D scores over 12 weeks were compared for the two treatment groups using mixed-effect models for longitudinal data. These models included time-trend parameter(s), treatment assignment, site, site-by-treatment assignment interaction, time-by-treatment assignment interaction, and other baseline variables reflecting possible differences in patients' demographic and clinical characteristics across sites. Second, endpoint analyses were conducted with outcomes of “response” and “remission.” Response, defined as a reduction of ≥50% in HAM-D score, is commonly used in clinical trials as a measure of change since baseline. In contrast, remission has traditionally been used as a measure of a treatment's ability to produce a state approximating an asymptomatic state. In this study, we defined remission as a HAM-D score <10 for 2 consecutive weeks, a cutoff point commonly used in geriatric clinical trials (30). Logistic regression was used to model factors associated with these endpoint outcomes. The omnibus statistic was used to test time-by-treatment interactions using intent-to-treat contrasts of response and remission at weeks 3, 6, 9, and 12. To assess moderation, baseline variables were checked for interactions with treatment effects. To determine the clinical utility of problem-solving therapy, number needed to treat was calculated for participants who completed assessments. Analyses were conducted using SAS, version 9.1 (SAS Institute, Cary, N.C.).
Results
Recruitment
Radio and newspaper advertisements and contact with providers generated interest in 653 older persons who were invited for screening (Figure 1). Of these, 183 were determined to be ineligible through an initial telephone screen because either they were not depressed (N=136) or they declined to participate (N=47) after hearing a description of the study. The remaining 470 underwent a structured clinical interview, which led to exclusion of 191 individuals: 40 did not meet criteria for major depression, 96 did not have executive dysfunction, 42 had another psychiatric diagnosis, and 13 declined to participate. Of the 279 who were eligible for the study, 58 (20.8%) did not undergo randomized assignment because they failed to complete baseline evaluation and did not return for further assessment or treatment. Of the 221 participants who underwent randomized assignment, 110 were assigned to the problem-solving therapy arm and 111 to the supportive therapy arm. Those who entered the trial had depression of moderate severity and executive function test scores indicating mild to moderate impairment (Table 1). There were no significant differences in demographic or clinical variables among participants assigned to the two treatment arms. Approximately 27% of participants had taken antidepressants in the past. A small proportion in each group had generalized anxiety disorder (7.4% in the problem-solving therapy group and 6.3% in the supportive therapy group). There were no statistically significant differences in demographic characteristics, depression severity, executive function, medical burden, or disability among participants who had taken antidepressants and those who were antidepressant naive.
| Variable | Problem-Solving Therapy (N=110) | Supportive Therapy (N=111) | ||
|---|---|---|---|---|
| Mean | SD | Mean | SD | |
| Age | 72.8 | 7.6 | 73.2 | 7.9 |
| Education (years) | 15.0 | 2.6 | 15.5 | 3.0 |
| Hamilton Depression Rating Scale score | 24.1 | 3.9 | 24.5 | 4.6 |
| Age at depression onset (years) | 58.3 | 20.9 | 53.3 | 23.6 |
| Total number depressive episodes | 2.1 | 2.7 | 2.3 | 1.6 |
| Mini-Mental State Examination score | 27.7 | 1.8 | 27.9 | 1.6 |
| Mattis Dementia Rating Scale, initiation/perseveration subscale score | 32.3 | 3.7 | 32.2 | 3.7 |
| Stroop Color-Word Test score | 21.9 | 8.6 | 22.2 | 7.9 |
| Wisconsin Card Sorting Test, perseverative errors | 15.4 | 9.7 | 13.7 | 8.4 |
| Trail Making Test, Part B, score | 139.4 | 63.3 | 135.7 | 64.0 |
| Frontal Systems Behavior Scale score | 40.0 | 9.4 | 39.8 | 8.8 |
| NEO Personality Inventory, neuroticism subscale score | 15.2 | 5.6 | 14.8 | 4.7 |
| Charlson comorbidity index score | 3.79 | 2.7 | 3.88 | 3.4 |
| World Health Organization Disability Assessment Schedule score | 27.0 | 7.7 | 26.2 | 7.0 |
Attrition
Of the 221 participants assigned to treatment, 91% remained in the study. Of those who stayed in the study, 9% dropped out of treatment (5% prior to week 4 of treatment and 4% after week 4). Of those who completed the treatment, 6% did not complete the 12-week assessment. There were no differences in attrition between the two treatment arms (Figure 1).
Treatment Outcomes
Severity of depression.
A mixed-effects model including treatment assignment, site, time, and time-by-treatment assignment interaction was significantly associated with the course of HAM-D scores over the 12-week period (F=14.13, df=204, p<0.0001; at week 9, Cohen's d=0.24; at week 12, d=0.39). Both treatments were associated with reduction of HAM-D scores (12-week problem-solving therapy mean=12.83 [SD=8.25]; 12-week supportive therapy mean=15.88 [SD=7.5]; time: F=73.80, df=204, p<0.0001). However, the time-by-treatment assignment interaction (F=7.41, df=196, p<0.007) indicated greater improvement in HAM-D scores in participants receiving problem-solving therapy (Figure 2). Treatment site did not significantly contribute to variance in HAM-D score over time.
Treatment response.
Response rates are reported in Table 2. Differences in response rates between the two treatment arms emerged by week 9, with a rate of 47.1% in the problem-solving therapy group and 29.3% in the supportive therapy group among participants who completed the 9-week assessment. Differences in response rates were also evident at week 12 among those who completed the assessment; the rate for the problem-solving therapy group was 56.7%, and for the supportive therapy group, 34.0%. The number needed to treat in order to reach response over 12 weeks was 4.4, indicating that problem-solving therapy yielded one additional response over supportive therapy for every 4.4 patients.
| Outcome Measure and Assessment Week | Problem-Solving Therapy Group (N=110) | Supportive Therapy Group (N=111) | Odds Ratio | 95% CI | χ2 | df | p | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Completed Assessment (N) | N | % | Completed Assessment (N) | N | % | ||||||
| Responded | |||||||||||
| 3 | 101 | 10 | 9.9 | 104 | 14 | 13.5 | 0.71 | 0.27-1.81 | 0.6 | 1 | 0.428 |
| 6 | 94 | 28 | 29.8 | 95 | 21 | 22.1 | 1.49 | 0.74-3.04 | 1.5 | 1 | 0.228 |
| 9 | 87 | 41 | 47.1 | 92 | 27 | 29.3 | 2.14 | 1.11-4.17 | 6.0 | 1 | 0.014 |
| 12 | 90 | 51 | 56.7 | 97 | 33 | 34.0 | 2.54 | 1.35-4.79 | 9.7 | 1 | 0.002 |
| Remitted | |||||||||||
| 3 | 101 | 9 | 8.9 | 104 | 9 | 8.7 | 1.03 | 0.35-3.08 | 0.0 | 1 | 0.948 |
| 6 | 94 | 20 | 21.3 | 95 | 16 | 16.8 | 1.33 | 0.60-2.98 | 0.6 | 1 | 0.437 |
| 9 | 87 | 33 | 37.9 | 92 | 20 | 21.7 | 2.20 | 1.09-4.50 | 5.6 | 1 | 0.017 |
| 12 | 90 | 41 | 45.6 | 97 | 27 | 27.8 | 2.17 | 1.13-4.18 | 6.3 | 1 | 0.012 |
a
Response and remission rates were calculated on the basis of those who completed assessments. Response was defined as a reduction of ≥50% in Hamilton Depression Rating Scale (HAM-D) score since baseline, and remission was defined as a HAM-D score <10.
Remission.
Remission rates were similarly distributed in the two treatment arms (Table 2). The remission rate at week 9 was 37.9% for the problem-solving therapy group and 21.7% for the supportive therapy group among those who completed the assessment. The remission rate at week 12 was 45.6% for the problem-solving therapy group and 27.8% for the supportive therapy group. The number needed to treat in order to achieve remission over 12 weeks was 5.6, indicating that problem-solving therapy yielded one additional remission over supportive therapy for every 5.6 patients.
Moderators of treatment outcome.
None of the demographic, cognitive, psychopathology, medical burden, or disability variables significantly moderated the efficacy of treatment (Table 3). Two variables did approach significance: total number of episodes (p=0.06) and baseline disability (p=0.05). In the problem-solving therapy group, slightly better depression outcomes were observed for participants with recurrent depression and those with greater disability, whereas in the supportive therapy group, depression outcomes tended to be slightly worse for these two subgroups.
| Moderator Variable | Analysis | ||
|---|---|---|---|
| Fa | df | p | |
| Age | 0.01 | 188 | 0.91 |
| Education (years) | 0.88 | 161 | 0.59 |
| Hamilton Depression Rating Scale score | 1.86 | 185 | 0.17 |
| Age at depression onset (years) | 0.18 | 132 | 0.67 |
| Total number depressive episodes | 3.55 | 147 | 0.06 |
| Mini-Mental State Examination score | 1.44 | 199 | 0.23 |
| Mattis Dementia Rating Scale, initiation/perseveration subscale | 0.62 | 201 | 0.43 |
| Stroop Color-Word Test score | 0.93 | 193 | 0.34 |
| Wisconsin Card Sorting Test, perseverative errors | 0.17 | 145 | 0.68 |
| Trail Making Test, Part B, score | 1.19 | 177 | 0.28 |
| Frontal Systems Behavior Scale score | 0.17 | 161 | 0.68 |
| NEO Personality Inventory, neuroticism subscale score | 2.36 | 184 | 0.13 |
| World Health Organization Disability Assessment Schedule score | 3.89 | 179 | 0.05 |
| Generalized anxiety disorder | 1.55 | 181 | 0.22 |
a
Effect estimate reflecting the change in the difference between the Hamilton Depression Rating Scale score slopes of the problem-solving therapy and supportive therapy groups when the moderator variable's score is increased by 1 point.
Discussion
The principal finding of this study is that problem-solving therapy was more effective than supportive therapy in reducing depressive symptoms and produced greater response and remission rates in older patients with major depression and executive dysfunction. This population is usually more disabled than older depressed patients without executive dysfunction and has greater disability because of the cognitive deficits. By the end of the 12-week trial, more than half of the patients who received problem-solving therapy met criteria for treatment response, and more than 45% met criteria for remission. Problem-solving therapy led to one more remission than supportive therapy for every 5–6 patients receiving these treatments. This is a robust difference, considering that in clinical trials comparing active antidepressant treatments, response rates are closer to 35% and the number needed to treat one person to remission is 10 (31). The efficacy demonstrated by problem-solving therapy is particularly important because depressed elderly patients with executive dysfunction have poor or slow response to pharmaco-therapy (3–6).
This is the first study to demonstrate the efficacy of problem-solving therapy in older patients with major depression and executive dysfunction. Our findings are consistent with previous research demonstrating that problem-solving therapy is effective for depressed, cognitively unimpaired older patients (11), older medical patients (12), older adults with macular degeneration (13), and older adults receiving home health care (32). In addition to efficacy in geriatric depression, problem-solving therapy has been shown to reduce psychopathology and distress in nondepressed patients with disorders accompanied by executive dysfunction, such as schizophrenia (14, 33). While problem-solving therapy was more efficacious than supportive therapy, supportive therapy led to substantial reductions in the severity of depressive symptoms and to acceptable response and remission rates by the end of the 12-week trial. In fact, supportive therapy was as efficacious as problem-solving therapy during the first 6 weeks of the trial. Supportive therapy has previously been shown to lead to clinically meaningful symptomatic improvement even when the comparator was found more efficacious (34, 35). As a consequence, supportive therapy has been recommended as an active intervention for some depressive disorders, including postpartum depression (36), and depression in day hospital patients (37). Therapeutic factors common to supportive therapy and problem-solving therapy may explain their comparable performance early in treatment. In both treatments, therapists are empathic, provide a safe environment for patients to discuss their concerns, and offer hope. These nonspecific therapeutic strategies are also important in facilitating continued engagement in psychotherapy and have a beneficial effect on mood over time (38), and they may explain why differences between the two treatments did not occur until later in the intervention.
The therapeutic advantage of problem-solving therapy over supportive therapy became apparent at weeks 9 and 12 of treatment. Most patients require approximately six sessions to learn the principles of problem solving. In subsequent sessions, patients consolidate use of the entire problem-solving therapy model by solving problems on their own in addition to those worked on with the therapist. The therapeutic effects of problem-solving therapy over supportive therapy occurred after the 6th week, at a time when participants were expected to have acquired adequate problem-solving skills. Therefore, a potential explanation for the late onset of therapeutic advantage of problem-solving therapy is development of new problem-solving skills through the problem-solving model. Our study's design does not allow us to determine whether problem-solving therapy owes its efficacy to improved problem-solving skills or to other components of the treatment, such as increased hopefulness, self-efficacy, problem resolution, and behavioral activation (10). Developing measures of these variables suitable for cognitively compromised older populations and identifying mediators of the efficacy of problem-solving therapy would be useful next steps. Beyond its theoretical value, such a study would identify the most salient features of problem-solving therapy, allowing further refinement of its use in community settings.
This study's main findings should be viewed in the context of its limitations. First, our therapists provided both treatments, a design that might have permitted therapist bias to influence the efficacy of interventions. As in other psychotherapy studies using our design, we attempted to mitigate bias by selecting therapists who did not have previous experience with either intervention, training them to high standards, and continuously monitoring their delivery of both treatments. Assigning each therapist to only one treatment arm would have resulted in a nested design requiring a very large sample size in order to control for therapist-specific effects (39). Furthermore, a nested design does not guarantee elimination of bias; therapists providing supportive therapy may have realized that they were the control condition had their participants not responded as well as anticipated.
Approximately 21% of older adults who met the study's selection criteria failed to enter the study because of limited interest or poor adherence to study procedures. However, 91% of those who started treatment remained in treatment until the end of the trial. Thus, our findings may be generalized mainly to patients who have sufficient interest and ability to be engaged in therapy. Furthermore, our sample was highly educated, thus limiting the general-izability of our findings to those with a college education. Although we assessed age at first depressive episode and whether the current episode was a recurrence, we have no information on the duration of the current episode, which may influence treatment outcome.
Study participants had mild executive dysfunction of unknown etiology. It remains unclear whether problem-solving therapy can be administered successfully to patients with more severe executive dysfunction or whether it is effective in patients for whom executive dysfunction evolves into dementia. We did not include a control arm of participants without executive dysfunction, and hence we are unable to determine whether patients with major depression and mild executive dysfunction do as well in problem-solving therapy and supportive therapy as those without executive dysfunction.
This study does not offer information on the stability of problem-solving therapy and supportive therapy effects after the end of the 12-week trial. Our encouraging results need to be followed by investigations of the stability of antidepressant response related to problem-solving therapy, need of maintenance problem-solving therapy, and appropriate maintenance dose of problem-solving therapy. Such studies are particularly warranted in elderly patients with depression and executive dysfunction, a population with a high propensity for relapse and recurrence (3). Finally, none of the participants were taking antidepressants; only a direct comparison of problem-solving therapy and antidepressant treatment can determine which intervention is better.
Of particular importance in understanding the role of a treatment is determining whether any patient characteristics influence how well patients respond to this treatment. Only a sparse literature exists on predictors and moderators of psychotherapy outcomes in depressed older adults. Comorbid personality disorder, generalized anxiety disorder, and early onset of first depressive episode have been found to compromise response to other psychotherapies (40, 41). Our results suggest interesting avenues for future exploration regarding problem-solving therapy's effects for other older adult populations. Problem-solving therapy appeared to have a slight advantage over supportive therapy for older adults with recurrent depression and older adults with functional impairments. In fact, participants with these clinical characteristics who received supportive therapy experienced a slight worsening of depressive symptoms over time. These data suggest that there may be opportunities for the development of treatment selection algorithms based on the clinical characteristics of patients seeking psychotherapy. As the effects were small, and given the complexity of moderation analyses, these results should be reviewed with caution. Future research regarding effects of patient characteristics on relative response to different psychotherapies could inform efforts toward individualized treatment.
Footnotes
Received Sept. 19, 2009; revision received Dec. 17, 2009; accepted March 25, 2010
Clinicaltrials.gov identifier: NCT00052091.
References
1.
Alexopoulos GS, Gunning-Dixon FM, Latoussakis V, Kanellopoulos D, Murphy CF: Anterior cingulate dysfunction in geriatric depression. Int J Geriatr Psychiatry 2008; 23:347–355
2.
Alexopoulos GS, Kiosses DN, Klimstra S, Kalayam B, Bruce ML: Clinical presentation of the “depression-executive dysfunction syndrome” of late life. Am J Geriatr Psychiatry 2002; 10:98–106
3.
Alexopoulos GS, Meyers BS, Young RC, Kalayam B, Kakuma T, Gabrielle M, Sirey JA, Hull J: Executive dysfunction and long-term outcomes of geriatric depression. Arch Gen Psychiatry 2000; 57:285–290
4.
Alexopoulos GS, Kiosses DN, Heo M, Murphy CF, Shanmugham B, Gunning-Dixon F: Executive dysfunction and the course of geriatric depression. Biol Psychiatry 2005; 58:204–210
5.
Potter GG, Kittinger JD, Wagner HR, Steffens DC, Krishnan KR: Prefrontal neuropsychological predictors of treatment remission in late-life depression. Neuropsychopharmacology 2004; 29:2266–2271
6.
Sneed JR, Roose SP, Keilp JG, Krishnan KR, Alexopoulos GS, Sackeim HA: Response inhibition predicts poor antidepressant treatment response in very old depressed patients. Am J Geriatr Psychiatry 2007; 15:553–563
7.
Alexopoulos GS, Murphy CF, Gunning-Dixon FM, Latoussakis V, Kanellopoulos D, Klimstra S, Lim KO, Hoptman MJ: Microstructural white matter abnormalities and remission of geriatric depression. Am J Psychiatry 2008; 165:238–244
8.
Drevets WC: Neuroimaging studies of mood disorders. Biol Psychiatry 2000; 48:813–829
9.
Alexopoulos GS, Raue PJ, Kanellopoulos D, Mackin S, Arean PA: Problem solving therapy for the depression-executive dys-function syndrome of late life. Int J Geriatr Psychiatry 2008; 23:782–788
10.
D'Zurilla TJ, Nezu AM: Problem-Solving Therapy: A Social Competence Approach to Clinical Intervention. New York, Springer, 1999
11.
Arean PA, Perri MG, Nezu AM, Schein RL, Christopher F, Joseph TX: Comparative effectiveness of social problem-solving therapy and reminiscence therapy as treatments for depression in older adults. J Consult Clin Psychol 1993; 61:1003–1010
12.
Arean P, Hegel M, Vannoy S, Fan MY, Unuzter J: Effectiveness of problem-solving therapy for older primary care patients with depression: results from the IMPACT project. Gerontologist 2008; 48:311–323
13.
Rovner BW, Casten RJ: Preventing late-life depression in age-related macular degeneration. Am J Geriatr Psychiatry 2008; 16:454–459
14.
Tarrier N, Sharpe L, Beckett R, Harwood S, Baker A, Yusopoff L: A trial of two cognitive behavioural methods of treating drug-resistant residual psychotic symptoms in schizophrenic patients, II: treatment-specific changes in coping and problem-solving skills. Soc Psychiatry Psychiatr Epidemiol 1993; 28:5–10
15.
Nezu AM, Nezu CM, Perri MG: Problem-Solving Therapy for Depression: Theory, Research, and Clinical Guidelines. New York, John Wiley & Sons, 1989
16.
Cuijpers P, van Straten A, Smit F: Psychological treatment of late-life depression: a meta-analysis of randomized controlled trials. Int J Geriatr Psychiatry 2006; 21:1139–1149
17.
Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56–62
18.
Folstein MF, Folstein SE, McHugh PR: “Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189–198
19.
Lineweaver TT, Bond MW, Thomas RG, Salmon DP: A normative study of Nelson's (1976) modified version of the Wisconsin Card Sorting Test in healthy older adults. Clin Neuropsychol 1999; 13:328–347
20.
Reitan R, Wolfson D: The Halstead-Reitan Neuropsychological Test Battery: Therapy and Clinical Interpretation. Tucson, Ariz, Neuropsychological Press, 1985
21.
Stout JC, Ready RE, Grace J, Malloy PF, Paulsen JS: Factor analysis of the Frontal Systems Behavior Scale (FrSBe). Assessment 2003; 10:79–85
22.
McCrae RR, John OP: An introduction to the five-factor model and its applications. J Pers 1992; 60:175–215
23.
Alexopoulos GS, Meyers BS, Young RC, Kakuma T, Feder M, Einhorn A, Rosendahl E: Recovery in geriatric depression. Arch Gen Psychiatry 1996; 53:305–312
24.
Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373–383
25.
Epping-Jordan JA, Ustun TB: The WHODAS-II: leveling the playing field for all disorders. World Health Organization Mental Health Bulletin 2000; 6:5–6
26.
Mattis S: Dementia Rating Scale. Odessa, Fla, Psychological Assessment Resources, 1989
27.
Perret E: The left frontal lobe of man and the suppression of habitual responses in verbal categorical behaviour. Neuropsychologia 1974; 12:323–330
28.
Hegel MT, Dietrich AJ, Seville JL, Jordan CB: Training residents in problem-solving treatment of depression: a pilot feasibility and impact study. Fam Med 2004; 36:204–208
29.
Marmar C, Weiss D, Gaston L: Towards the validation of the California Therapeutic Alliance Rating System. Psychol Assess 1989; 1:46–52
30.
Lecrubier Y: How do you define remission? Acta Psychiatr Scand Suppl 2002; 415:7–11
31.
Thase ME, Entsuah R, Cantillon M, Kornstein SG: Relative anti-depressant efficacy of venlafaxine and SSRIs: sex-age interactions. J Womens Health (Larchmt) 2005; 14:609–616
32.
Gellis ZD, McGinty J, Misener E, Bruce M: Problem-solving therapy for late-life depression in home care: a randomized field trial. Am J Geriatr Psychiatry 2007; 15:968–978
33.
van der Gaag M, Kern RS, van den Bosch RJ, Liberman RP: A controlled trial of cognitive remediation in schizophrenia. Schizophr Bull 2002; 28:167–176
34.
Kendrick T, Chatwin J, Dowrick C, Tylee A, Morriss R, Peveler R, Leese M, McCrone P, Harris T, Moore M, Byng R, Brown G, Barthel S, Mander H, Ring A, Kelly V, Wallace V, Gabbay M, Craig T, Mann A: Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study. Health Technol Assess 2009; 13:iii-iv, ix-xi, 1–159
35.
Freedland KE, Skala JA, Carney RM, Rubin EH, Lustman PJ, Davila-Roman VG, Steinmeyer BC, Hogue CW: Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Arch Gen Psychiatry 2009; 66:387–396
36.
Freeman MP, Davis MF: Supportive psychotherapy for perinatal depression: preliminary data for adherence and response. Depress Anxiety 2010; 27:39–45
37.
Brajkovic L, Jevtovic S, Bilic V, Bras M, Loncar Z: The efficacy of a brief supportive psychodynamic therapy in treating anxious-depressive disorder in daily hospital. Coll Antropol 2009; 33:245–251
38.
Oei TPS, Shuttlewood GJ: Specific and nonspecific factors in psychotherapy: a case of cognitive therapy for depression. Clin Psychol Rev 1996; 16:83–103
39.
Bhaumik DK, Roy A, Aryal S, Hur K, Duan N, Normand S, Brown H, Gibbons RD: Sample size determination for studies with repeated continuous outcomes. Psychiatr Ann 2008; 38:765–771
40.
Gum AM, Arean PA, Bostrom A: Low-income depressed older adults with psychiatric comorbidity: secondary analyses of response to psychotherapy and case management. Int J Geriatr Psychiatry 2007; 22:124–130
41.
Reynolds CF, Dew MA, Frank E, Begley AE, Miller MD, Cornes C, Mazumdar S, Perel JM, Kupfer DJ: Effects of age at onset of first lifetime episode of recurrent major depression on treatment response and illness course in elderly patients. Am J Psychiatry 1998; 155:795–799
Information & Authors
Information
Published In
History
Received: 19 September 2009
Revision received: 17 December 2009
Accepted: 25 March 2010
Published online: 1 November 2010
Published in print: November 2010
Authors
Funding Information
Dr. McCulloch has received research funding from Amgen for statistical methodology. Dr. Alexopoulos has received grant support from or served in a consulting or speaking capacity for Bristol-Myers Squibb, Cephalon, Forest, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis, Pfizer, and Sanofi-Aventis and holds equity in Johnson & Johnson. All other authors report no financial relationships with commercial interests.Supported by NIMH grants R01 MH064099, R01 MH063982, K24 MH074717, and P30 MH085943 and the Sanchez Foundation.
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBGet Access
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).